Melphalan-based autologous stem cell transplant (Mel-ASCT) is a standard therapy for multiple myeloma, but is associated with severe oral mucositis (OM). To identify predictors for severe OM, we studied 381 consecutive newly diagnosed myeloma patients who received Mel-ASCT. Melphalan was given at 200 mg/m 2 body surface area (BSA), reduced to 140 mg/m 2 for serum creatinine 43 mg/dl. Potential covariates included demographics, pre-transplant serum albumin and renal and liver function tests, and mg/kg melphalan dose received. The BSA dosing resulted in a wide range of melphalan doses given (2.4-6.2 mg/kg). OM developed in 75% of patients and was severe in 21%. Predictors of severe OM in multiple logistic regression analyses were high serum creatinine (odds ratio (OR) ¼ 1.581; 95% confidence interval (CI): 1.080-2.313; P ¼ 0.018) and high mg/kg melphalan (OR ¼ 1.595; 95% CI: 1.065-2.389; P ¼ 0.023). An OM prediction model was developed based on these variables. We concluded that BSA dosing of melphalan results in wide variations in the mg/kg dose, and that patients with renal dysfunction who are scheduled to receive a high mg/ kg melphalan dose have the greatest risk for severe OM following Mel-ASCT. Pharmacogenomic and pharmacokinetic studies are needed to better understand interpatient variability of melphalan exposure and toxicity.
Introduction
The importance of melphalan dose intensity for patients with multiple myeloma is supported by the increase in remission rates, event-free and overall survival with high-dose melphalan and autologous stem cell transplant (Mel-ASCT) compared to low-dose melphalan and prednisone. 1, 2 This improved response is further enhanced when tandem Mel-ASCT is applied, suggesting that higher melphalan doses would be desirable if well tolerated. The dose-limiting toxicity of melphalan is oral mucositis (OM), which can be severe, 3 especially in patients with renal failure (melphalan is excreted by the kidneys). High-dose melphalan as a single agent is considered as one of the most mucotoxic conditioning regimens. 4 The pain of OM is the single most bothersome symptom after ASCT, 5 and OM is associated with prolonged hospitalization and increased cost of care, [6] [7] [8] [9] [10] often resulting in dose reduction or interruption of therapy with a negative impact on cancer outcome. 11 OM also acts as an entry portal for serious infections. 6, 12 Other negative consequences of OM include dysgeusia, difficulty speaking and receiving nutrition, hydration and oral medications. 9 Opiates, the agents of choice for controlling OM pain, may result in various adverse events. 13 Despite the critical role of Mel-ASCT in the therapy of myeloma, the risk factors for OM, the dose-limiting toxicity of Mel-ASCT, have not been identified. We sought to identify the risk factors for melphalan-induced OM among 381 consecutive myeloma patients undergoing Mel-ASCT.
Patients and methods

Study design
The study population consisted of adult patients with newly diagnosed multiple myeloma cared for at the Myeloma Institute for Research and Treatment (MIRT) between October 1998 and December 2002. All patients were enrolled in our study UARK 98-026 (Total Therapy II) protocol.
14 Medical records of the first 381 consecutive patients undergoing their first Mel-ASCT were reviewed with approval from the Institutional Review Board. One patient who received 100 mg/m 2 of melphalan was excluded from this analysis. The Total Therapy II protocol consists of four phases. Induction with four cycles of chemotherapy: (1) /day and dexamethasone 40 mg/day, followed by collection of peripheral stem cell and (4) a second cycle of DCEP. Following induction, patients received tandem ASCT with melphalan 200 mg/m 2 of body surface area (BSA) for patients with serum creatinine o3 mg/dl and reduced to 140 mg/m 2 for patients with serum creatinine 43 mg/dl. Melphalan was administered in one dose on day À1 of ASCT. The consolidation phase was given for a year and was followed by maintenance therapy with dexamethasone and alpha interferon.
At study enrollment, patients were randomized to receive thalidomide or no thalidomide 400 mg/day through the induction phase. Thalidomide was withheld 1 week before Mel-ASCT and resumed during the post transplant consolidation and maintenance phases.
All patients received antimicrobial prophylaxis consisting of acyclovir, fluconazole and a fluoroquinolone (levofloxacin or gatifloxacin) throughout the period of neutropenia. During the ASCT period, patients used prophylactic Biotene mouthwash (lysozyme, lactoferrin, glucose oxidase and lactoperoxidase) up to five times a day and the Magic Mouthwash Solution (lidocaine solution, diphenhydramine hydrochloride and aluminum hydroxide suspension) up to five times a day if signs or symptoms of OM were present. Patients were evaluated every other day or more often if clinically indicated by the ASCT team, until engraftment, and longer if clinically indicated.
Melphalan dosing
The melphalan dose given was calculated according to the Mosteller's formula of BSA 15 as follows:
The actual body weight (ABW) was used for patients whose weight was p60 kg, whereas calculated body weight (CBW) was utilized for patients weighing 460 kg. CBW was derived from ideal body weight (IBW) according to the formula: CBW ¼ (ABWÀIBW) Â 0.4 þ IBW. The following formula for calculating IBW was used: IBW ¼ 50 kg þ 2.3 Â (inchesÀ60) for men and IBW ¼ 45.5 kg þ 2.3 Â (inchesÀ60) for women. The body mass index (BMI) was calculated as ABW (in kg) divided by height squared (in meters). 16 Mucositis assessment OM that developed after the first Mel-ASCT was evaluated for this study. The follow-up period included days 0-60 (day 0: day of infusion of stem cells).
Medical records were reviewed by two research nurses with extensive training and experience in the evaluation of mucositis. Peak OM was graded according to the Common Toxicity Criteria from the National Cancer Institute CTC Version 2.0, 30 April 1999 (http://ctep.cancer.gov/forms/ CTCv20_4-30-992.pdf) in which Grade 0 ¼ no mucositis; Grade 1 ¼ painless ulcers, erythema or mild soreness in the absence of lesions; Grade 2 ¼ painful erythema, edema or ulcers but can eat and swallow; Grade 3 ¼ painful erythema, edema or ulcers requiring intravenous hydration and Grade 4 ¼ severe ulceration or requires parenteral or enteral nutritional support or prophylactic endotracheal intubation. Grade 3 and 4 are considered severe mucositis.
Risk factors
Pre-ASCT variables including age, gender, race, weight, BSA, BMI, renal and liver function tests, serum albumin and melphalan dose received (in mg/kg) response to induction chemotherapy and thalidomide allocation at enrollment.
Pre-ASCT data refer to those obtained immediately before the infusion of melphalan.
Statistical analysis
Analysis of the risk factors for severe OM was performed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Binary logistic regression analysis was used to assess the relation between pre-determined variables and risk for severe mucositis. Gender and race were analyzed as categorical variables. All other variables were analyzed as continuous variables. Risk factors for severe OM were evaluated by univariate logistic regression analysis and variables with P-value p0.25 were entered into multiple logistic regression analysis by stepwise selection to identify independent risk factors. The identification of independent risk factors allowed the development of the best-fitted predictive model for severe mucositis. Significance level was chosen as Pp0.05.
Results
Patient characteristics
Three hundred and eighty-one consecutive newly diagnosed adult myeloma patients were evaluated. The M component of 56% of the patients was IgG, followed by IgA (24%), free light chains only (16%), non-secretory (3%) and IgD (1%). Pre-transplant characteristics analyzed as potential risk factors are shown in Tables 1 and 2 . All patients engrafted after Mel-ASCT. Forty-six patients (12%) received prophylactic colony-stimulating factors (granulocyte or granulocyte-macrophage) that did not affect mucositis severity (data not shown). Incidence and risk factors for OM OM was present in 75% of the patients and was severe in 21%. Of interest, 25% of the patients remained mucositisfree regardless of the melphalan mg/kg dose ( Figure 2 ) and of the serum creatinine level (data not shown).
Melphalan dose
Univariate analysis identified three potential risk factors for severe OM: higher mg/kg melphalan dose and higher serum creatinine and alkaline phosphatase ( Table 2 ). The predictive variables for severe OM in the multiple logistic regression analyses were higher serum creatinine (odds ratio (OR) ¼ 1.581; 95% confidence interval (CI): 1.080-2.313; P ¼ 0.018) and higher mg/kg melphalan dose Table 1 Pre-transplant characteristics of 381 myeloma patients undergoing high-dose melphalan and ASCT
Continuous variables
Mean7s (OR ¼ 1.595; 95% CI: 1.065-2.389; P ¼ 0.023) ( Table 3) . Using logistic regression analysis, a mucositis predictive model based on these two independent risk factors was developed with a receiver operating characteristic curve of 0.61.
Discussion
This is the first study to identify the incidence, severity and risk factors for severe OM following Mel-ASCT and the first study of OM to be conducted in a large, homogeneous patient population enrolled in one treatment protocol with the same underlying disease, extent of prior therapy, induction, mobilization and single-agent conditioning regimen, and supportive care standards. The use of single-agent conditioning eliminates the confounding factors for OM that can be associated with multi-agent regimens. 4, 17 Two new findings emerged from our study: (a) BSA dosing resulted in a wide variation in the mg/kg melphalan dose given, with significantly lower doses received by overweight and obese patients; and (b) higher mg/kg melphalan dose, and renal dysfunction (both reflecting increased melphalan exposure) were the key pre-transplant risk factors for severe OM following Mel-ASCT. Our results also showed that the majority of patients developed OM, in agreement with prior reports by us and others, 3, [18] [19] [20] [21] and that a quarter of the patients remained mucositis-free despite receiving higher mg/kg doses of melphalan and/or having higher serum creatinine.
Our new finding of a wide variation in mg/kg melphalan given and the correlation between severe OM and higher mg/kg of melphalan suggest that BSA dosing may not be the optimal method for dosing melphalan. In a study conducted in dogs with cancer, melphalan was administered at various mg/m 2 using a BSA formula. Disproportionately greater myelosuppression was observed in small dogs (P ¼ 0.016) leading the investigators to conclude that although both BSA and weight were significantly correlated with severity of toxicity, melphalan-induced toxicity can be more accurately estimated by body weight than by BSA (P ¼ 0.008 vs P ¼ 0.022, respectively) and that melphalan should be dosed on a weight basis and not on BSA. 22 That BSA may not be the optimal dosing method for melphalan and other antineoplastic agents is supported by the lack of correlation between BSA dosing and variables associated with drug exposure, including renal and/or liver function tests, key pharmacokinetic parameters (clearance, area under the curve, others) and drug-related toxicity. 23, 24 Furthermore, the BSA formula is not standardized and has been associated with variable toxicity and response among patients at extremes of weight, depending on how the formula is applied. Adjustment for body weight using IBW results in lower toxicity and response among obese patients, [25] [26] [27] probably as a result of the relatively lower doses of antineoplastic agents received. In contrast, obese patients suffer increased toxicity when no adjustment for IBW is made. 28, 29 Given the rapidly growing problem of obesity in the developed world, the use of BSA for dosing antineoplastic agents is likely to result in under or overdosing of a large proportion of patients. Of note, 38% of our study population was overweight and 25% obese.
The increased OM risk related to higher mg/kg doses of melphalan is supported by reports describing higher rates of severe OM with escalating doses of melphalan, from almost none at [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] The role of renal dysfunction as a risk factor for OM is not surprising given the renal excretion of melphalan [33] [34] [35] [36] [37] and the higher rates of OM observed among Mel-ASCT among patients with renal failure. 38, 39 Our OM prediction model can identify those high-risk patients for the targeted application of preventive measures and for the optimal development of clinical trials evaluating 40 and/or response to inflammation 41, 42 could be responsible for the variable individual susceptibility to mucositis. This is reflected by the receiver operated characteristic of 0.61, that is, the two variables (renal function and melphalan mg/kg dose) could predict OM with 61% certainty.
Our findings suffer the limitations inherent to retrospective studies, including the inability to retrieve accurate data on pre-existing oral pathology, or on opiate usage for the control of OM pain. We did not evaluate the effect of mg/kg melphalan dose on event-free and overall survival as the treatment protocol (Total Therapy II) includes four cycles of induction chemotherapy, consolidation and maintenance phases, all of which with agents other than melphalan. The treatment protocol further randomizes patients to thalidomide or no thalidomide therapy. Of note, thalidomide has been shown to have a beneficial effect on myeloma outcome, 43 including in the current Total Therapy II study. 44 Our findings have several implications. The high rate of OM in our patient population highlights the need for evaluation of mucoprotective agents, such as keratinocyte growth factor, 45 amifostine 20 or interleukin-11. 46 In addition, the wide variation in the melphalan mg/kg dose received implies the need to explore modifications of or alternatives to BSA dosing for recipients of high-dose melphalan, whether given in the autologous or in the allogeneic setting with potentially important implications for the development of graft-versus-host disease and other complications of allogeneic transplantation. Finally, differences in the intensity of induction therapy before Mel-ASCT, method of dosage adjustment for BSA (actual vs ideal or CBW) and mucositis score used (WHO, NCI, OMAS, etc.) should be described in publications addressing toxicities of antineoplastic agents as these variables may result in different rates of toxicity including OM.
In conclusion, BSA dosing of melphalan results in wide variations in the mg/kg dose of melphalan. Patients scheduled to receive higher mg/kg melphalan dose (per BSA dosing) for ASCT should be considered at higher risk for severe OM, particularly if they suffer renal dysfunction. Pharmacogenomic and pharmacokinetics studies are needed to better understand interpatient variability of melphalan exposure and toxicity.
